Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 148 No. 0506 (2018)

Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren’s syndrome: examination of data from the UK Primary Sjögren’s Syndrome Registry

  • Alexandre Dumusc
  • Wan-Fai Ng
  • Katherine James
  • Bridget Griffiths
  • Elizabeth Price
  • Colin T. Pease
  • Paul Emery
  • Peter Lanyon
  • Adrian Jones
  • Michele Bombardieri
  • Nurhan Sutcliffe
  • Costantino Pitzalis
  • Monica Gupta
  • John McLaren
  • Annie Cooper
  • Ian Giles
  • David Isenberg
  • Vadivelu Saravanan
  • David Coady
  • Bhaskar Dasgupta
  • Neil McHugh
  • Steven Young-Min
  • Robert J. Moots
  • Nagui Gendi
  • Mohammed Akil
  • Francesca Barone
  • Benjamin A. Fisher
  • Saaeha Rauz
  • Andrea Richards
  • Simon J. Bowman
  • on behalf of the UK primary Sjögren’s Syndrome Registry
Cite this as:
Swiss Med Wkly. 2018;148:w14588



To assess the use of the Clinical EULAR Sjögren’s Syndrome Disease Activity Index (ClinESSDAI), a version of the ESSDAI without the biological domain, for assessing potential eligibility and outcomes for clinical trials in patients with primary Sjögren’s syndrome (pSS), according to the new ACR-EULAR classification criteria, from the UK Primary Sjögren’s Syndrome Registry (UKPSSR).


A total of 665 patients from the UKPSSR cohort were analysed at their time of inclusion in the registry. ESSDAI and ClinESSDAI were calculated for each patient.


For different disease activity index cut-off values, more potentially eligible participants were found when ClinESSDAI was used than with ESSDAI. The distribution of patients according to defined disease activity levels did not differ statistically (chi2 p = 0.57) between ESSDAI and ClinESSDAI for moderate disease activity (score ≥5 and <14; ESSDAI 36.4%; ClinESSDA 36.5%) or high disease activity (score ≥14; ESSDAI 5.4%; ClinESSDAI 6.8%). We did not find significant differences between the indexes in terms of activity levels for individual domains, with the exception of the articular domain. We found a good level of agreement between both indexes, and a positive correlation between lymphadenopathy and glandular domains with the use of either index and with different cut-off values. With the use of ClinESSDAI, the minimal clinically important improvement value was more often achievable with a one grade improvement of a single domain than with ESSDAI. We observed similar results when using the new ACR-EULAR classification criteria or the previously used American-European Consensus Group (AECG) classification criteria for pSS.


In the UKPSSR population, the use of ClinESSDAI instead of ESSDAI did not lead to significant changes in score distribution, potential eligibility or outcome measurement in trials, or in routine care when immunological tests are not available. These results need to be confirmed in other cohorts and with longitudinal data.


  1. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004;164(12):1275–84. doi:.
  2. Bowman SJ, Everett CC, O’Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren’s Syndrome. Arthritis Rheumatol. 2017;69(7):1440–50. doi:.
  3. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233–42. doi:.
  4. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270–6. doi:.
  5. Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526–31. doi:.
  6. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al.; EULAR Sjögren’s Task Force. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–9. doi:.
  7. Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015;1(1):e000022. doi:.
  8. Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73(2):472–4. doi:.
  9. Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Boostma H, et al., European League Against Rheumatism Sjögren’s Task Force. Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index. Arthritis Care Res (Hoboken). 2010;62(4):551–8. doi:.
  10. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, et al.; EULAR Sjögren’s Task Force. Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2015;74(5):859–66. doi:.
  11. Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al.; EULAR Sjögren’s Task Force. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382–9. doi:.
  12. Seror R, Meiners P, Baron G, Bootsma H, Bowman SJ, Vitali C, et al.; EULAR Sjögren Task Force. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Ann Rheum Dis. 2016;75(11):1945–50. doi:.
  13. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al.; European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8. doi:.
  14. Ng WF, Bowman SJ, Griffiths B ; UKPSSR study group. United Kingdom Primary Sjogren’s Syndrome Registry--a united effort to tackle an orphan rheumatic disease. Rheumatology (Oxford). 2011;50(1):32–9. doi:.
  15. Oni C, Mitchell S, James K, Ng WF, Griffiths B, Hindmarsh V, et al.; UK Primary Sjögren’s Syndrome Registry. Eligibility for clinical trials in primary Sjögren’s syndrome: lessons from the UK Primary Sjögren’s Syndrome Registry. Rheumatology (Oxford). 2016;55(3):544–52.
  16. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al.; International Sjögren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16. doi:.
  17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327(8476):307–10. doi:.
  18. Gottenberg JE, Seror R, Saraux A, et al. Evolution of Disease Activity over a 5-Year Period in the 395 Patients with Primary Sjögren’s Syndrome of the ASSESS Prospective Cohort [abstract]. Arthritis Rheumatol. 2016;68(suppl 10):abstract no. 2693.
  19. Baldini C, Ferro F, Luciano N, et al. Clinically Meaningful Improvement of ESSDAI and ESSPRI in Patients with Primary Sjögren’s Syndrome in Real Life: A 12-Month Longitudinal Study [abstract]. Arthritis Rheumatol. 2016;6(suppl 10):abstract no. 2679.